Keywords
chronic heart and failure
chronic renal failure
apoAI
NTproBNP
hs-CRP
Abstract
Accelerated atherosclerosis and increased cardiovascular events have been extensively documented in patients with end stage chronic kidney disease. The aim of our work was to find evidence supporting the theory that chronic heart failure (CHF) induces renal function damage. In our work, lipids, apolipoprotein (apo)AI, NTproBNP, hsCRP, lipid hydroperoxide (LPO) and creatinine levels were determined in patients with CHF. A total of 37 patients who were diagnosed with CHF, as well as 15 healthy persons, were recruited for the study. The patients were placed into 2 groups: patients with NYHA class 2 and NYHA class 3. Using routine laboratory methods, NT-proBNP level, and lipids were measured by way of employing a Cobas Integra analyser, while the concentration of hs-CRP was measured by immunonephelometric methods. Moreover, serum LPO concentration was measured using Cayman’s Assay Kit (LPO). The statistical analysis of the obtained results was performed using the nonparametric Kruskal-Wallis test and Spearman’s correlation analysis. Our work demonstrated that the CHF patients had significantly decrease concentration of HDL cholesterol and apoAI, but increased NT-pro-BNP, hsCRP and LPO levels. In all CHF patients, a significant positive correlation between NTproBNP concentration and creatinine levels, and a significant negative correlation between NTproBNP concentration and apoAI levels, as well as between concentration of creatinine and apoAI levels, was shown. The study results suggest that variation in the concentration of NTproBNP, LPO, hsCRP, apoAI, creatinine, in addition to chronic heart failure progression, gradually accompany the progress of chronic renal failure. What is more, the disorders may lead to the occurrence of cardiovascular events, consequently, to patient death.References
1. Koenig W., High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int. J. Cardiol., 168, 5126, 2013.
2. Yamamoto S., Kon V. Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Curr. Opin. Nephrol. Hypertens., 18, 181, 2009.
3. Foley RN., Parfrey PS., Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J.Am. Soc.Nephrol., 9, S16, 1998.
4. Anavekar NS., McMurray JJ., Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med., 351, 1285, 2004.
5. Klausen KP., Scharling H., Jensen JS. Very low level of microalbuminuria is associated with increase of risk of death in subjects with cardiovascular or cerebrovascular diseases. J. Intern. Med., 260, 231, 2006.
6. Keith DS., Nichols GA., Gullion CM., et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch. Intern. Med., 164, 659, 2004.
7. Weiner DE., Tighiouart H., Elsayed EF., Griffith JL., Salem DN., Levey AS., Sarnak MJ. The relationship between non-traditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am. J. Kidney Dis., 51, 212, 2008.
8. Kalantar-Zadeh K., Block G., Horwich T., Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J. Am. Coll. Cardiol., 43, 1439, 2004.
9. Tsimihodimos V., Dounousi E., Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am. J. Nephrol., 28, 958, 2008.
10. Chan DT., Irish AB., Dogra GK., Watts GF. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis, 196, 823, 2008.
11. Okubo K., Ikewaki K., Sakai S., Tada N., Kawaguchi Y., Mochizuki S. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J. Am. Soc. Nephrol., 15, 1008, 2004.
12. Navab M., Reddy S., Van Lenten BJ., Anantharamaiah GM., Fogelman AM. Role of dysfunctional HDL in atherosclerosis. J. Lipid. Res., 50, S145, 2009.
13. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High: Density LipoproteinIntervention Trial. Am. J. Cardiol., 86, 19L, 2000.
14. Kimak E., Hałabiś M., Baranowicz-Gąszczyk I. Relationship between serum lipid, lipoprotein, triglyceride-rich lipoprotein, and high-density lipoprotein particle concentrations in post-renal transplant patients. J. ZUS-B, 11, 249, 2010.
15. Kimak E., Hałabiś M., Baranowicz-Gąszczyk I., Solski J., Książek A. Association between moderately oxidized low-density lipoprotein and high-density lipoprotein particle subclass distribution in hemodialyzed and post-renal transplant patients. J. ZUS-B., 12, 365, 2011.
16. Kimak E., Bylina J., Solski J., Hałabis´ M., Baranowicz-Gaąszczyk I., Ksiażek A. Association between lipids, lipoproteins composition of HDL particles and triglyceride-rich lipoproteins, and LCAT and CETP activity in post-renal transplant patients. Cell. Biochem. Biophys. 67, 695, 2013.
17. Luis F., Ramos LF., Shintani A., Ikizler TA., Himmelfarb J. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J. Am. Soc. Nephrol. 19, 593, 2008.
18. Li H, Horke S, Feorstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis, 237, 208, 2014.
19. Rosenson R. S., Stafforini D. M., Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J. Lipid. Res. 53, 1767, 1782. 2012.
20. Tousoulis D., Psaltopoulou T., Androulakis E., Papageorgiou N, Papaioannou S, Oikonomou E, Synetos A, Stefanadis Ch. Oxidative stress and early atherosclerosis: novel antioxidant treatment. Cardiovasc. Drugs. Ther., 29, 75, 2015.
21. Shlipak MG., Fried LF., Cushman M., Manolio TA., Peterson D., Stehman-Breen C., Bleyer A., Newman A., Siscovick D., Psaty B. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA., 293, 1737, 2005.
22. LaRosa JC., Grundy SM., Waters DD., Shear C., Barter P., Fruchart JC., Gotto AM., Greten H., Kastelein JJ., Shepherd J., Wenger N. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med., 352, 1425, 2005.
23. MatsushitaK., Ballew SH., Coresh J. Influence of Chronic Kidney Disease on Cardiac Structure and Function. Curr. Hypertens. Rep, 17, 581, 2015, doi:10.1007/s11906-015-0581-x.
24. Schmieder RE., Mitrovic V., Hengstenberg V. Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin. Clin. Res. Cardiol., 104, 621, 2015.
25. Guazzi M., Gatto P., Giusti G., Pizzamiglio F., Previtali I., Vignati C., Arena R. Pathophysiology of cardiorenal syndrome in decompensated heart failure: role of lung–right heart–kidney interaction. Int. J. Cardiol., 169, 379, 2013.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2016 Authors